Table 1.
Day 1 clinical and laboratory features of patients with ALF due to ischemic hepatitis
| Total (n = 51) | Spontaneous survivors (n = 36) | Died/transplanted (n = 15) | P | |
|---|---|---|---|---|
| Age (years) | 50 ± 16 | 51 ± 17 | 46 ± 15 | 0.29 |
| Female | 63% | 61% | 67% | 0.71 |
| Race/ethnicity | ||||
| Caucasian | 82% | 86% | 73% | 0.28 |
| African American | 10% | 11% | 7% | 0.63 |
| Asian | 2% | 3% | – | – |
| Other | 6% | – | 20% | – |
| Symptom onset to enrollment (days) | 8 ± 7 | 9 ± 8 | 6 ± 5 | 0.18 |
| Hospital admission to enrollment (days) | 5 ± 6 | 4 ± 3 | 7 ± 9 | 0.08 |
| Medical history | ||||
| Heart disease | 31% | 33% | 27% | 0.64 |
| Hypertension | 25% | 28% | 20% | 0.56 |
| Diabetes | 14% | 17% | 7% | 0.34 |
| Renal disease | 10% | 11% | 7% | 0.63 |
| Day 1 labs | ||||
| Hemoglobin (g/dl) | 10.6 ± 1.6 | 10.7 ± 1.5 | 10.5 ± 1.9 | 0.69 |
| WBC (103/ml) | 15.5 ± 12.2 | 13.6 ± 6 | 20.1 ± 20.3 | 0.08 |
| Platelet count (103/ml) | 96.1 ± 57.6 | 105.8 ± 59 | 73 ± 48.1 | 0.06 |
| INR | 2.8 ± 1.9 | 2.8 ± 2.2 | 2.7 ± 1.1 | 0.91 |
| ALT (IU/l) | 3,014 ± 2.325 | 2,543 ± 1,538 | 4,146 ± 3,440 | 0.10 |
| AST (IU/l) | 3,681 ± 3,825 | 3,326 ± 3,877 | 4,511 ± 3,695 | 0.32 |
| Alkaline phosphatase (IU/l) | 180 ± 134 | 142 ± 78 | 263 ± 188 | 0.03 |
| Total bilirubin (mg/dl) | 6 ± 7 | 5 ± 4 | 10.6 ± 10.2 | 0.05 |
| Creatinine (mg/dl) | 2.9 ± 1.5 | 2.7 ± 1.4 | 3.3 ± 1.6 | 0.15 |
| Phosphate (mg/dl) | 4.8 ± 2.8 | 4 ± 1.7 | 6.6 ± 3.8 | 0.03 |
| HCO3 (mmol/l) | 21.5 ± 5.6 | 22.5 ± 5.1 | 19 ± 6 | 0.06 |
| Arterial pH | 7.38 ± 0.10 | 7.39 ± 0.08 | 7.38 ± 0.13 | 0.67 |
| Day 1 clinical status | ||||
| Mean arterial pressure (mm Hg) | 87 ± 16 | 88 ± 14 | 83 ± 21 | 0.44 |
| Pulse (BPM) | 101 ± 19 | 100 ± 19 | 103 ± 20 | 0.63 |
| Grade 3–4 encephalopathy | 55% | 39% | 93% | 0.0004 |
| Cardiac arrhythmia | 33% | 28% | 47% | 0.19 |
| On pressors | 33% | 33% | 33% | 1.00 |
| On dialysis | 25% | 25% | 27% | 0.90 |
| Intubated | 71% | 64% | 87% | 0.10 |